Group 1 - The core viewpoint highlights a significant shift towards "health consumption" during the recent National Day and Mid-Autumn Festival holidays, indicating a growing public awareness of health and a transformation in consumer attitudes [1] - During the 8-day holiday, traditional health products such as bird's nest, Ejiao cake, and Western ginseng saw explosive sales growth, with a year-on-year increase of 205% [1] - Modern nutritional supplements like lysine, protein powder, and glucosamine also experienced strong sales, with year-on-year growth rates of 200%, 85%, and 76% respectively, reflecting consumers' preference for practical and caring health products [1] Group 2 - The health consumption trend continues with the upcoming 11.11 shopping festival, where consumers can participate in promotional activities while purchasing health-related products [2] - During the 11.11 event, the number of limited-time free draw opportunities will double, and the maximum cash back amount will triple, enhancing the consumer experience [2]

Group 1 - Beijing Yaojing JD Health Comprehensive Clinic Co., Ltd. has been established with a registered capital of 5 million yuan [1] - The business scope includes clinic services, remote health management services, and retail of clothing and accessories [1] - The company is wholly owned by Suqian JD Tianning Health Technology Co., Ltd. [1]

Core Insights - The annual incidence of lung cancer in China reaches 1.06 million, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases, and the EGFR gene mutation being the most common driver gene with a mutation rate of about 50% [1] - There is a pressing demand for innovative treatment options with better efficacy and lower side effects for the large patient population [1] Group 1 - In August, JD Health signed a strategic cooperation agreement with Johnson & Johnson Innovation Pharmaceuticals to explore new product launches and academic exchanges, aiming to build a patient-centered healthcare service system [1] - JD Health will leverage its comprehensive pharmaceutical supply chain and nationwide distribution network to ensure that innovative specialty drugs, including Lico®, can safely and efficiently reach users across the country [1] Group 2 - On October 9, Johnson & Johnson's innovative targeted drug Lico® (lanzetini mesylate tablets) was launched online on JD Health, designed for first-line treatment of EGFR mutation-positive advanced NSCLC in combination with evinacumab [3] - Lico® offers significant survival benefits and safety advantages, providing a breakthrough treatment option for the large lung cancer patient population in China [3] - JD Health aims to enhance the accessibility of this innovative treatment solution, allowing more Chinese lung cancer patients to benefit from it as early as possible [3]

Core Insights - Johnson & Johnson's innovative targeted drug, Lico® (lanzetini mesylate tablets), has been launched online on JD Health, providing a breakthrough treatment option for a large population of lung cancer patients in China [1][2] - The drug is used in combination with evan monoclonal antibody for first-line treatment of EGFR mutation-positive advanced non-small cell lung cancer (NSCLC), offering significant overall survival benefits and safety advantages [1] - JD Health aims to enhance the accessibility of this innovative treatment through its "first station for new specialty drugs" capabilities, ensuring more lung cancer patients can benefit from it [1] Industry Context - According to the 2024 National Cancer Report, there are 1.06 million new lung cancer patients annually in China, with approximately 85% being non-small cell lung cancer [1] - The mutation rate of the EGFR gene, the most common driver gene in NSCLC, is about 50%, indicating a high demand for more effective and safer innovative treatment options [1] - In August, JD Health signed a strategic cooperation agreement with Johnson & Johnson's Innovative Pharmaceuticals to leverage JD Health's supply chain and service capabilities alongside Johnson & Johnson's innovative drug portfolio in oncology and other key disease areas [1]

Core Viewpoint - Johnson & Johnson's innovative targeted drug, Lico (Lanzetini Mesylate Tablets), has been launched online on JD Health, providing a breakthrough treatment option for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) [1] Group 1: Product Launch - Lico is positioned as a first-line treatment in combination with Avelumab for advanced NSCLC, offering significant overall survival benefits and safety advantages [1] - The online launch on JD Health aims to enhance accessibility for a large population of lung cancer patients in China [1] Group 2: Strategic Partnership - JD Health and Johnson & Johnson Innovation Pharmaceuticals signed a strategic cooperation agreement in August, leveraging JD Health's supply chain and service capabilities [1] - The partnership will explore new product launches and academic exchanges, focusing on building a patient-centered healthcare service system [1]

Core Insights - The "Heart Maze Art Exhibition" in Wuhan features a special event led by Peng Kaiping, a prominent figure in positive psychology, focusing on emotional regulation techniques [1][3] - The exhibition, running from October 6 to October 10, aims to transform abstract psychological theories into immersive experiences, guiding visitors through a journey of emotional awareness and self-integration [3][4] - Peng Kaiping's "Aroma Therapy" is highlighted as a core method in the exhibition, utilizing olfactory senses to facilitate quick emotional adjustments based on neuroscience principles [3] Group 1 - The exhibition is a collaboration between JD Health, Wuhan University People's Hospital, and Wuhan Mental Health Center, emphasizing the theme of discovering one's true self beneath emotional fog [3] - The "Regulation" experience area features Peng Kaiping's therapy, which bypasses complex cognitive processes to directly evoke emotional memories [3] - Discussions at the event addressed common issues like weak social connections, with an emphasis on integrating health management and psychological adjustment into daily life [4] Group 2 - Peng Kaiping clarified misconceptions about positive psychology, stressing the need for a deeper understanding of mental health as a daily maintenance requirement, similar to physical health [4] - The exhibition combines art and science to create a tangible space for psychological well-being, allowing visitors to find personalized paths to harmonize with their emotions [4]

公司名稱: 京东健康股份有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06618 | | 說明 | | | | | | | | | 多櫃檯證券代號 | 86618 | RMB | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 100,000,000,000 | USD | | 0.0000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | | 0 | | | | USD | | 0 | | 本月底結存 ...

智通财经APP讯，京东健康(06618)发布公告，于2025年10月1日，本公司根据首次公开发售后股份奖励 计划向承授人授出了涉及29.91万股新股份的29.91万股奖励股份，约占于授出日期已发行股份总数的 0.01%。 ...

京东健康(06618)发布公告，于2025年10月1日，本公司根据首次公开发售后股份奖励计划向承授人授出 了涉及29.91万股新股份的29.91万股奖励股份，约占于授出日期已发行股份总数的0.01%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 授出股份獎勵 董事會宣佈，於2025年10月1日，本公司根據首次公開發售後股份獎勵計劃向承授人授出 了涉及299,090股新股份的299,090股獎勵股份，約佔於授出日期已發行股份總數的0.01%。 授出的詳情如下： 附註：由於授出日期並非交易日，該金額為2025年9月30日（即緊接授出日期前的交易日）的收市價。 授出的理由及裨益 授出旨在通過股份所有權、股息及就股份支付的其他分派及╱或股份價值增加，使承授 人的利益與本集團的利益相一致，並鼓勵和留住承授人為本集團的長期增長和利潤作 出貢獻。 授出7,126股獎勵股份的歸屬期間少於12個月，原因為該等 股份為出於行政管理原因在一年內分批授出的部分獎勵。 表現目標： 授出並無附帶表現目 ...